JP2024516356A5 - - Google Patents

Info

Publication number
JP2024516356A5
JP2024516356A5 JP2023562314A JP2023562314A JP2024516356A5 JP 2024516356 A5 JP2024516356 A5 JP 2024516356A5 JP 2023562314 A JP2023562314 A JP 2023562314A JP 2023562314 A JP2023562314 A JP 2023562314A JP 2024516356 A5 JP2024516356 A5 JP 2024516356A5
Authority
JP
Japan
Prior art keywords
antisense strand
double
seq
khk
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2023562314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/059663 external-priority patent/WO2022218941A2/en
Publication of JP2024516356A publication Critical patent/JP2024516356A/ja
Publication of JP2024516356A5 publication Critical patent/JP2024516356A5/ja
Abandoned legal-status Critical Current

Links

JP2023562314A 2021-04-12 2022-04-11 ケトヘキソキナーゼ(khk)を阻害するための組成物及び方法 Abandoned JP2024516356A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173775P 2021-04-12 2021-04-12
US63/173,775 2021-04-12
US202163182277P 2021-04-30 2021-04-30
US63/182,277 2021-04-30
EP21196784.9 2021-09-15
EP21196784 2021-09-15
PCT/EP2022/059663 WO2022218941A2 (en) 2021-04-12 2022-04-11 Compositions and methods for inhibiting ketohexokinase (khk)

Publications (2)

Publication Number Publication Date
JP2024516356A JP2024516356A (ja) 2024-04-15
JP2024516356A5 true JP2024516356A5 (https=) 2025-04-22

Family

ID=81448852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562314A Abandoned JP2024516356A (ja) 2021-04-12 2022-04-11 ケトヘキソキナーゼ(khk)を阻害するための組成物及び方法

Country Status (20)

Country Link
US (2) US20220340909A1 (https=)
EP (1) EP4323518A2 (https=)
JP (1) JP2024516356A (https=)
KR (1) KR20230170732A (https=)
CN (1) CN117120612A (https=)
AU (1) AU2022256742A1 (https=)
BR (1) BR112023017367A2 (https=)
CA (1) CA3214439A1 (https=)
CL (1) CL2023003017A1 (https=)
CO (1) CO2023013465A2 (https=)
CR (1) CR20230482A (https=)
DO (1) DOP2023000223A (https=)
EC (1) ECSP23076906A (https=)
IL (1) IL307315A (https=)
JO (1) JOP20230250A1 (https=)
MX (1) MX2023012048A (https=)
PE (1) PE20250400A1 (https=)
PH (1) PH12023552830A1 (https=)
TW (1) TW202305135A (https=)
WO (1) WO2022218941A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022226098A1 (en) * 2021-02-26 2023-08-24 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202430192A (zh) 2022-10-11 2024-08-01 德商百靈佳殷格翰國際股份有限公司 用於治療nash之劑量方案
TW202430191A (zh) 2022-10-11 2024-08-01 德商百靈佳殷格翰國際股份有限公司 用於治療伴有晚期纖維化及/或硬化之nash的方法
WO2024175062A1 (zh) * 2023-02-23 2024-08-29 大睿生物医药科技(上海)有限公司 调控KHK基因活性的dsRNA分子
WO2024260379A1 (zh) * 2023-06-20 2024-12-26 施能康医药科技(苏州)有限公司 靶向已酮糖激酶的核酸及其用途
CN117925620B (zh) * 2024-01-30 2024-09-03 大连医科大学 一种果糖激酶khk的小干扰和短发夹rna序列组合及其应用
WO2025184876A1 (zh) * 2024-03-07 2025-09-12 竣莅医药科技(无锡)有限公司 一种rna干扰触发分子与对应核酸干扰药物制剂及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
DK2341943T3 (en) 2008-09-22 2019-02-25 Dicerna Pharmaceuticals Inc COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
CN113057959B (zh) * 2014-02-11 2024-07-16 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
AU2015330670B2 (en) * 2014-10-10 2022-01-06 Novo Nordisk Health Care Ag Therapeutic inhibition of lactate dehydrogenase and agents therefor
DK3569711T3 (da) * 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc Ligandmodificerede dobbeltstrengede nukleinsyrer
HUE059718T2 (hu) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok
US20210332367A1 (en) * 2018-09-18 2021-10-28 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AU2020358016A1 (en) * 2019-10-02 2022-04-21 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering RNA with minimal fluorine content
BR112022017822A2 (pt) * 2020-03-06 2022-11-08 Alnylam Pharmaceuticals Inc Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
AU2022226098A1 (en) * 2021-02-26 2023-08-24 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2024516356A5 (https=)
JP7442574B2 (ja) Lpaの遺伝子発現の阻害のための組成物及び方法
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
JP2021518125A5 (https=)
JP2023103244A5 (https=)
TWI680767B (zh) 用於增強的細胞攝取之化合物及方法
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
TW201920227A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
JP2023530461A5 (https=)
JP7830340B2 (ja) PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法
JP2023514336A5 (https=)
RU2015154721A (ru) КОМПОЗИЦИИ НА ОСНОВЕ RNAi SERPINA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2023506181A5 (https=)
JP2023506258A5 (https=)
JP2023500661A5 (https=)
TW202305135A (zh) 用於抑制己酮醣激酶(khk)之組合物及方法
JP2023529903A5 (https=)
JP2024538859A5 (https=)
JP7560616B2 (ja) 膜貫通型セリンプロテアーゼ6(tmprss6)発現を阻害するための組成物および方法
JP2024514880A5 (https=)
JP2024522996A5 (https=)
JP2024528701A5 (https=)
JPH11512601A (ja) 修飾プロテインキナーゼa特異的オリゴヌクレオチドおよびその使用法
WO2025103391A1 (zh) 用于抑制lpa的基因表达的sirna,含其的组合物及其用途
TW202519663A (zh) 雙股寡核苷酸試劑及其用途